A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/55 A61K45/06

A61P17/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 02/053170 A (ANSORGE SIEGFRIED; LENDECKEL UWE (DE); NEUBERT KLAUS (DE); REINHOLD D) 11 July 2002 (2002-07-11)	6-12
, <u> </u>	1-5,13, 14
page 1 - page 2, line 2 page 4, last paragraph - page 5 page 8 - page 9, paragraph 1 page 11, paragraph 1 page 13	
DE 100 25 464 A (INST MEDIZINTECHNOLOGIE MAGDEB) 6 December 2001 (2001-12-06) claims 1-13	1-4,6-14
	WO 02/053170 A (ANSORGE SIEGFRIED; LENDECKEL UWE (DE); NEUBERT KLAUS (DE); REINHOLD D) 11 July 2002 (2002-07-11) page 1 - page 2, line 2 page 4, last paragraph - page 5 page 8 - page 9, paragraph 1 page 11, paragraph 1 page 13 DE 100 25 464 A (INST MEDIZINTECHNOLOGIE MAGDEB) 6 December 2001 (2001-12-06) claims 1-13

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filling date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	 *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
15 February 2005	01/03/2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer
NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hars, J

l	Init onal Application No
l	PCT/EP2004/007377

	Ion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 939 560 A (JENKINS PAUL D ET AL) 17 August 1999 (1999-08-17) cited in the application column 1, line 6 - line 27 column 2, line 25 - line 28 column 2, line 64 - line 65	1-3,6-8, 11-14
	RAYNAUD F ET AL: "CHARACTERIZATION OF SPECIFIC PROTEASES ASSOCIATED WITH THE SURFACE OF HUMAN SKIN FIBROBLASTS AND THEIR MODULATION IN PATHOLOGY" JOURNAL OF CELLULAR PHYSIOLOGY, vol. 151, no. 2, 1992, pages 378-385, XP009040761 ISSN: 0021-9541 abstract	1-14
X	FUJII HIDEJI ET AL: "Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors" BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 19, no. 1, 1996, pages 6-10, XP001204025 ISSN: 0918-6158 abstract	1,4-6,9, 11-14
X	WO 03/045228 A (BRIGHAM & WOMENS HOSPITAL; TUFTS COLLEGE (US); KUCHROO VIJAY K (US);) 5 June 2003 (2003-06-05) page 3, line 18 - line 23 page 7, line 24 - line 29	1-3,5-8, 10-14
A	DIMON-GADAL STEPHANIE ET AL: "MAP kinase abnormalities in hyperproliferative cultured fibroblasts from psoriatic skin" JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 110, no. 6, June 1998 (1998-06), pages 872-879, XP002308341 ISSN: 0022-202X abstract	1-14
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1983, SAISON M ET AL: "IDENTIFICATION OF CELL SURFACE DI PEPTIDYL PEPTIDASE IV EC-3.4.14.5 IN HUMAN FIBROBLASTS" XP002308342 Database accession no. PREV198477050630 abstract & BIOCHEMICAL JOURNAL, vol. 216, no. 1, 1983, pages 177-184, ISSN: 0264-6021	1-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2004/007377

BEST AVAILABLE COP'

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
Thisinte	mational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. 🗶	Claims Nos.: 1-14 (partly) because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 1-5, 13, 14 relate to a method for treatment of the human or animal body, the search was carried out and was based on the stated effects of the compound or composition.
2. X	Claims Nos.: 1-14 (partly) because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
s	ee additional PCT/ISA/210 sheet
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Вох П	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	·
	·
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Continuation of Box II.1

Although claims 1-5, 13, 14 relate to a method for treatment of the human or animal body, the search was carried out and was based on the stated effects of the compound or composition.

Continuation of Box II.2

Claims 1-14 (in part)

The current claims 1-14 relate to substances characterized in each case by a desirable property or characteristic, namely:

- inhibitors of enzymes having the same substrate specificity (DP IV-analogue enzyme activity)
- inhibitors of enzymes have the same substrate specificity (APN-analogue enzyme activity).

Therefore the claims encompass all substances that have this characteristic or property, but the application provides support by the description (PCT Article 5) for only a limited number of such substances. In the present case the claims lack the proper support and the application lacks the requisite disclosure to such an extent that it appears impossible to carry out a meaningful search covering the entire range of protection sought.

Moreover, the claims also lack the requisite clarity (PCT Article 6) since they attempt to define the substances by the desired result in each case. This lack of clarity is also such that it is impossible to carry out a meaningful search covering the entire range of protection sought. Therefore the search was directed to the part of the claims that appear to be clear, supported or disclosed in the above sense, namely the parts concerning the substances:

- inhibitors of DP IV
- inhibitors of APN.

BEST AVAILABLE COP

The applicant is advised that claims relating to inventions in respect of which no international search report has been established normally need not be the subject of an international preliminary examination (PCT Rule 66.1(e)). In its capacity as International Preliminary Examining Authority the EPO generally will not carry out a preliminary examination for subjects that have not been searched. This also applies to cases where the claims were amended after receipt of the international search report (PCT Article 19) or where the applicant submits new claims in the course of the procedure under PCT Chapter II. After entry into the regional phase before the EPO, however, an additional search can be carried out in the course of the examination (cf. EPO Guidelines, Part C, VI, 8.5) if the deficiencies that led to the declaration under PCT Article 17(2) have been remedied.

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02053170	A	11-07-2002	DE	10100052	A1	11-07-2002
NO 02000170	••	•• • • • • • • • • • • • • • • • • • • •	DE	10102392		14-08-2002
			DE	10155093		12-06-2003
			CA	2436724		11-07-2002
			CN	1484533		24-03-2004
			WO	02053170		11-07-2002
			ΕP	1349576		08-10-2003
			JP	2004520330		08-07-2004
			US	2004132639		08-07-2004
DE 10025464	Α	06-12-2001	DE	10025464	A1	06-12-2001
		•	AU	6747501	Α	03-12-2001
			AU	2001267475	B2	04-11-2004
			CA	2410305	A1	22-11-2002
			CN	1430519	T	16-07-2003
			WO	0189569	A1	29-11-2001
			EP	1289559	A1	12-03-2003
			JP	2003534293	T	18-11-2003
			US	2005014699	A1	20-01-2005
US 5939560	A	17-08-1999	AU	1113395	Α	19-06-1995
•			AU	8421998		12-11-1998
			CA	2178066		08-06-1995
			CN	1141033		22-01-1997
			CZ	9601595		15-01-1997
			EP	0731789		18-09-1996
			FI	962315		05-08-1996
			WO	9515309		08-06-1995
			HU	76274		28-07-1997
			JP	9509921	Ţ	07-10-1997
			NO	962269		30-07-1996
			PL	314838		30-09-1996
			RU	2156237		20-09-2000
			TW	397811		11-07-2000
			US	6201132		13-03-2001
			ZA 	9409525	A	02-08-1995
WO 03045228	Α	05-06-2003	AU	2002360453		10-06-2003
			CA	2466870		05-06-2003
			EP	1487471		22-12-2004
			WO	03045228	A 2	05-06-2003